[헤럴드경제=손인규 기자]Shinpoong Pharm’s antimalarial treatment’Piramax (ingredient names pyronaridin altesunate) is expected to undergo a phase 3 clinical trial in Africa to see the effect of the treatment of a novel coronavirus infection (Corona 19).
According to industry sources on the 6th, the UK Liverpool University Research Institute recently registered a phase 3 clinical trial on the world’s largest clinical trial registration site, Clinical Trials, in Kenya and Burkina Faso, Africa to confirm the therapeutic effect of Pyramax for COVID-19 patients. . Clinical trials are scheduled to start on the 8th of this month (local time) and continue until July 2023.
This clinical trial targets 142 patients with both corona and malaria infections, three times a day, for three days, 71 control patients who were prescribed the antimalarial drug “Artemer Lumepanthrin” and “pyrronaridin altesunate”. The effect of corona treatment is confirmed by comparing the prescribed experimental group.
The research team plans to evaluate how much Piramax can eliminate the coronavirus within 7 days. The Bill & Melinda Gates Foundation, the US Centers for Disease Control and Prevention, the Kenya Institute of Medicine, and the Kenya Centers for Disease Control and Prevention will participate in this clinical trial.
– .
